{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:03:21Z","timestamp":1772309001861,"version":"3.50.1"},"reference-count":21,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1620\/tjem.234.313","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T09:16:55Z","timestamp":1418980615000},"page":"313-317","source":"Crossref","is-referenced-by-count":16,"title":["Elevated Levels of Carbonyl Proteins in Cerebrospinal Fluid of Patients with Neurodegenerative Diseases"],"prefix":"10.1620","volume":"234","author":[{"given":"Paulus S","family":"Rommer","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Vienna"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Greilberger","sequence":"additional","affiliation":[{"name":"Institute for Physiological Chemistry, Medical University Graz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Salhofer-Polanyi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Auff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Leutmezer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Herwig","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical University of Vienna"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","unstructured":"Calabrese, V., Bella, R., Testa, D., Spadaro, F., Scrofani, A., Rizza, V. &amp; Pennisi, G. (1998) Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress. <i>Drugs Exp. Clin. Res.<\/i>, 24, 125-131."},{"key":"2","unstructured":"Calabrese, V., Raffaele, R., Cosentino, E. &amp; Rizza, V. (1994) Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. <i>Int. J. Clin. Pharmacol. Res.<\/i>, 14, 119-123."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Drechsel, D.A., Est\u00e9vez, A.G., Barbeito, L. &amp; Beckman, J.S. (2012) Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. <i>Neurotox. Res.<\/i>, 22, 251-264.","DOI":"10.1007\/s12640-012-9322-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Gonsette, R.E. (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. <i>J. Neurol. Sci.<\/i>, 274, 48-53.","DOI":"10.1016\/j.jns.2008.06.029"},{"key":"5","unstructured":"Greilberger, J., Fuchs, D., Leblhuber, F., Greilberger, M., Wintersteiger, R. &amp; Tafeit, E. (2010) Carbonyl proteins as a clinical marker in Alzheimer\u2019s disease and its relation to tryptophan degradation and immune activation. <i>Clin. Lab.<\/i>, 56, 441-445."},{"key":"6","doi-asserted-by":"crossref","unstructured":"Greilberger, J., Koidl, C., Greilberger, M., Lamprecht, M., Schroecksnadel, K., Leblhuber, F., Fuchs, D. &amp; Oettl, K. (2008) Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer\u2019s disease. <i>Free Radic. Res.<\/i>, 42, 633-638.","DOI":"10.1080\/10715760802255764"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Hirotani, M., Maita, C., Niino, M., Iguchi-Ariga, S., Hamada, S., Ariga, H. &amp; Sasaki, H. (2008) Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients. <i>Mult. Scler.<\/i>, 14, 1056-1060.","DOI":"10.1177\/1352458508093616"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Lassmann, H., van Horssen, J. &amp; Mahad, D. (2012) Progressive multiple sclerosis: pathology and pathogenesis. <i>Nat. Rev. Neurol.<\/i>, 8, 647-656.","DOI":"10.1038\/nrneurol.2012.168"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Lublin, F.D. &amp; Reingold, S.C. (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. <i>Neurology<\/i>, 46, 907-911.","DOI":"10.1212\/WNL.46.4.907"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Ortiz, G.G., Mac\u00edas-Islas, M.A., Pacheco-Mois\u00e9s, F.P., Cruz-Ramos, J.A., Sustersik, S., Barba, E.A. &amp; Aguayo, A. (2009) Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. <i>Dis. Markers<\/i>, 26, 35-39.","DOI":"10.1155\/2009\/325847"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Pennisi, G., Cornelius, C., Cavallaro, M.M., Salinaro, A.T., Cambria, M.T., Pennisi, M., Bella, R., Milone, P., Ventimiglia, B., Migliore, M.R., Di Renzo, L., De Lorenzo, A. &amp; Calabrese, V. (2011) Redox regulation of cellular stress response in multiple sclerosis. <i>Biochem. Pharmacol.<\/i>, 82, 1490-1499.","DOI":"10.1016\/j.bcp.2011.07.092"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Perry, G., Cash, A.D. &amp; Smith, M.A. (2002) Alzheimer disease and Oxidative stress. <i>J. Biomed. Biotechnol.<\/i>, 2, 120-123.","DOI":"10.1155\/S1110724302203010"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Petzold, A. (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. <i>J. Neurol. Sci.<\/i>, 233, 183-198.","DOI":"10.1016\/j.jns.2005.03.015"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F.D., Montalban, X., O\u2019Connor, P., Sandberg-Wollheim, M., Thompson, A.J., et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Ann. Neurol.<\/i>, 69, 292-302.","DOI":"10.1002\/ana.22366"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Poulsen, K., Bahl, J.M., Tanassi, J.T., Simonsen, A.H. &amp; Heegaard, N.H. (2012) Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. <i>Methods<\/i>, 56, 284-292.","DOI":"10.1016\/j.ymeth.2011.12.009"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Rejdak, K., Eikelenboom, M.J., Petzold, A., Thompson, E.J., Stelmasiak, Z., Lazeron, R.H., Barkhof, F., Polman, C.H., Uitdehaag, B.M. &amp; Giovannoni, G. (2004) CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. <i>Neurology<\/i>, 63, 1439-1445.","DOI":"10.1212\/01.WNL.0000142043.32578.5D"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Rejdak, K., Petzold, A., Stelmasiak, Z. &amp; Giovannoni, G. (2008) Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. <i>Mult. Scler.<\/i>, 14, 59-66.","DOI":"10.1177\/1352458507082061"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Sbardella, E., Greco, A., Stromillo, M.L., Prosperini, L., Puopolo, M., Cefaro, L.A., Pantano, P., De Stefano, N., Minghetti, L. &amp; Pozzilli, C. (2013) Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. <i>Mult. Scler.<\/i>, 19, 411-417.","DOI":"10.1177\/1352458512457721"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Weiner, H.L. (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? <i>Ann. Neurol.<\/i>, 65, 239-248.","DOI":"10.1002\/ana.21640"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Weinshenker, B.G. (1998) The natural history of multiple sclerosis: update 1998. <i>Semin. Neurol.<\/i>, 18, 301-307.","DOI":"10.1055\/s-2008-1040881"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Zeman, D., Adam, P., Kalistov\u00e1, H., Sobek, O., Kelbich, P., Andel, J. &amp; Andel, M. (2000) Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients. <i>Acta Neurol. Scand.<\/i>, 101, 89-94.","DOI":"10.1034\/j.1600-0404.2000.101002089.x"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/234\/4\/234_313\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T20:02:20Z","timestamp":1619640140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/234\/4\/234_313\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.234.313","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}